(2Z)-2-(2-hydroxy-5-nitrobenzylidene)-1-benzothiophen-3(2H)-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: (2Z)-2-(2-hydroxy-5-nitrobenzylidene)-1-benzothiophen-3(2H)-one
• 英文别名: (2Z)-2-[(2-hydroxy-5-nitrophenyl)methylidene]-1-benzothiophen-3-one
• 化学式: C15H9NO4S
• 分子量: 299.3
• InChiKey: PENIBPKELSMGQC-ZSOIEALJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  108
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Chemical Reporters of Protein Acylation
  申请人：HANG HOWARD C.

  公开号：US20100203647A1

  公开（公告）日：2010-08-12

  Methods and kits for detecting acylated proteins produced by cells that have been cultured or by cells within an organism are provided. Also provided are methods and kits for detecting acylated proteins produced by cells where affinity purification tags are that facilitate detection are used. Compounds useful for the detection of acylated proteins are also provided.

  提供了用于检测已被培养的细胞产生的酰化蛋白或生物体内细胞产生的酰化蛋白的方法和试剂盒。还提供了用于检测已使用亲和纯化标签的细胞产生的酰化蛋白的方法和试剂盒，以便进行检测。还提供了用于检测酰化蛋白的化合物。
• Compositions and methods for inhibiting DHHC-type palmitoyltransferases for cancer treatment
  申请人：DANA-FARBER CANCER INSTITUTE, INC.

  公开号：US11384126B2

  公开（公告）日：2022-07-12

  The present invention relates to compositions and methods for inhibiting DHHC3 palmitoyltransferase for treating cancer. Described herein, are methods of inhibiting expression or activity of programmed death-ligand 1 (PD-L1) in a cell of a subject, e.g., a human subject, in need thereof are carried out by administering to the subject an effective amount of a palmitoyltransferase inhibitor, thereby inhibiting the expression or activity of PD-L1 in the subject. The palmitoyltransferase comprises an Asp-His-His-Cys motif (DHHC)-type protein. Exemplary DHHC-type proteins include DHHC3, DHHC5, DHHC7, and DHHC17.

  本发明涉及用于治疗癌症的抑制 DHHC3 棕榈酰基转移酶的组合物和方法。本发明描述了通过向受试者施用有效量的棕榈酰基转移酶抑制剂，从而抑制程序性死亡配体1（PD-L1）在受试者（例如人类受试者）细胞中的表达或活性的方法。棕榈酰基转移酶包括Asp-His-His-Cys motif (DHHC)型蛋白。示例性 DHHC 型蛋白包括 DHHC3、DHHC5、DHHC7 和 DHHC17。
• COMPOSITIONS AND METHODS FOR INHIBITING DHHC-TYPE PALMITOYLTRANSFERASES FOR CANCER TREATMENT
  申请人：DANA-FARBER CANCER INSTITUTE, INC.

  公开号：US20210032298A1

  公开（公告）日：2021-02-04

  The present invention relates to compositions and methods for inhibiting DHHC3 palmitoyltransferase for treating cancer. Described herein, are methods of inhibiting expression or activity of programmed death-ligand 1 (PD-L1) in a cell of a subject, e.g., a human subject, in need thereof are carried out by administering to the subject an effective amount of a palmitoyltransferase inhibitor, thereby inhibiting the expression or activity of PD-L1 in the subject. The palmitoyltransferase comprises an Asp-His-His-Cys motif (DHHC)-type protein. Exemplary DHHC-type proteins include DHHC3, DHHC5, DHHC7, and DHHC17.